Several other research firms have also recently issued reports on MRK. Oddo Bhf set a €125.00 ($148.81) price objective on Merck KGaA and gave the stock a buy rating in a report on Friday, November 10th. Morgan Stanley set a €103.00 ($122.62) target price on Merck KGaA and gave the company a neutral rating in a report on Monday, September 25th. Credit Suisse Group set a €106.00 ($126.19) target price on Merck KGaA and gave the company a neutral rating in a report on Wednesday, July 26th. Goldman Sachs Group set a €105.00 ($125.00) target price on Merck KGaA and gave the company a neutral rating in a report on Thursday, August 17th. Finally, Kepler Capital Markets set a €119.00 ($141.67) target price on Merck KGaA and gave the company a buy rating in a report on Monday, July 31st. Eleven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of €108.52 ($129.20).
Merck KGaA (MRK) traded down €0.04 ($0.05) during mid-day trading on Tuesday, hitting €89.39 ($106.42). The stock had a trading volume of 703,336 shares. Merck KGaA has a 1-year low of €87.99 ($104.75) and a 1-year high of €115.00 ($136.90).
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with our FREE daily email newsletter.